Insights

Evernorth Specialty Services patient spotlight: Dave

May 28, 2025

Meet Dave, an Accredo patient living with common variable immune deficiency (CVID). With the support of Accredo's specialized team, Dave is better enabled to live life on his own terms.

Image
An elderly man with gray hair and a mustache sitting on a couch in a room with a bookcase.

Living with a complex health condition can be challenging and overwhelming. For Dave, who was diagnosed with common variable immune deficiency, managing his health used to mean trips to the hospital for monthly infusions and significant disruptions to his daily life. 

Today, Dave receives his immunoglobulin medicine from Accredo Specialty Pharmacy. He self-infuses the medication in the comfort of his home, which has been a game-changer, giving him the freedom to live life on his own terms. 

He relies on Accredo’s team of specialized pharmacists, nurses, patient care advocates, and more, who are an essential partner in his care.

Watch the video to learn more about Dave’s health journey and how Accredo is always there for him. 

Tags
Specialty
See how our solutions can help
Accredo

Accredo raises the standard in specialty pharmacy, delivering care beyond the prescription and additive savings beyond the trend. Through our pharmacy model, plan sponsors can count on competitive specialty drug pricing and access to the specialty therapies your members need. We provide condition- and drug-focused expertise that prepares you for what’s ahead while driving the most value for you now. Our pharmacy engine propels savings to you and delivers well-being support for your members at no cost.

Related Articles
Image
Two women in white shirts smiling and walking together in a sunlit park.
Article
Understanding and addressing caregiver distress in oncology care
May 11, 2026
Image
Smiling woman doctor with stethoscope around neck, holding tablet talking to woman
Article
Why integrating behavioral health into cancer care matters for health plans
May 07, 2026
Image
black male in lab
Article
Cell and gene therapy pipeline outlook for plan sponsors
May 01, 2026